![]() Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. | ![]() Intellia Therapeutics Intellia Therapeutics is a genome editing company that caters to the biotechnology industry. | ![]() Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. | ![]() Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. | Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals is a biopharmaceutical company that specializes in drug development. | ![]() Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | ||||
Founding Date | Founding Date 1989 | Founding Date 1942 | Founding Date 2014 | Founding Date 2010 | Founding Date 1992 | Founding Date 1980 | Founding Date 2002 | Founding Date 2001 | Founding Date 2002 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||||
Locations | Locations Carlsbad, US HQ | Locations Trevose, US HQ Philadelphia, US | Locations Cambridge, US HQ | Locations Somerville, US HQ | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US | Locations Plano, US HQ Irving, US Plano, US | Locations Pasadena, US HQ Madison, US San Diego, US | ||
Employees | Employees 92716% increase | Employees 56031% decrease | Employees 40323% decrease | Employees 1,2763% decrease | Employees 32338% decrease | Employees 1,31413% increase | Employees 3217% decrease | Employees 13416% increase | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 6.3 b | Valuation ($) 7.4 m | Valuation ($) 1.7 b | Valuation ($) 4.9 b | Valuation ($) 95.4 m | Valuation ($) 12.4 b | Valuation ($) 6.6 b | Valuation ($) 2.5 b | Valuation ($) 36.5 b |
Financial | |||||||||
Revenue (est.) | Revenue (est.) $705.1m (FY, 2024) | Revenue (est.) $340.6m (FY, 2022) | Revenue (est.) $57.9m (FY, 2024) | Revenue (est.) $560.2m (FY, 2024) | Revenue (est.) $83.8m (FY, 2024) | Revenue (est.) $1.9b (FY, 2024) | Revenue (est.) $2.2m (FY, 2022) | Revenue (est.) $3.6m (FY, 2024) | Revenue (est.) $2.2b (FY, 2024) |
Cost of goods | Cost of goods $11.2m (FY, 2024) | Cost of goods $294.5m (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods $89.4m (FY, 2024) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $306.5m (FY, 2024) |
Gross profit | Gross profit $693.9m (FY, 2024) | Gross profit $33.2m (FY, 2022) | Gross profit N/A | Gross profit N/A | Gross profit ($5.6m) (FY, 2024) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $1.9b (FY, 2024) |
Net income | Net income ($453.9m) (FY, 2024) | Net income ($231.6m) (FY, 2022) | Net income ($519m) (FY, 2024) | Net income ($569.2m) (FY, 2024) | Net income ($240.7m) (FY, 2024) | Net income $235.2m (FY, 2024) | Net income ($311.9m) (FY, 2022) | Net income ($609.7m) (FY, 2024) | Net income ($278.2m) (FY, 2024) |
Operating ⚠ | |||||||||
Patents Issued | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued 240 (FY, 2016) | Patents Issued 359 (FY, 2016) | Patents Issued N/A |
Phase I Trials Products | Phase I Trials Products 1 (FY, 2023) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 13 (FY, 2023) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 9 (FY, 2023) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Funding | |||||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 200.1m | Total funding raised $ 409m | Total funding raised N/A | Total funding raised $ 468.9m | Total funding raised $ 147.1m | Total funding raised $ 1.5b |
Lannett is a company that specializes in pharmaceutical product families.
View companyIntellia Therapeutics is a genome editing company that caters to the biotechnology industry.
View companyUltragenyx Pharmaceutical is a company that develops therapies for rare genetic diseases.
View companyBluebird Bio is a developer of gene therapies for severe genetic diseases.
View company